Environmental Impact on Vascular Development Predicted by High-Throughput Screening by Kleinstreuer, Nicole C. et al.
1596  v o l u m e  119 | n u m b e r 11 | November 2011  •  Environmental Health Perspectives
Research
We currently face significant challenges in 
understanding develop  mental health risks 
associated with the thousands of diverse 
compounds entering the environment 
(Martin et al. 2009b). Traditional prenatal 
animal testing is a resource-intensive, low- 
throughput approach that yields limited mech-
anistic information about biological pathways 
and potential adverse consequences in humans, 
motivating a new paradigm for toxicity evalua-
tion (National Research Council 2007). To 
this end, the U.S. Environmental Protection 
Agency (EPA) ToxCast™ research project (Dix 
et al. 2007) and the federal Tox21 consortium 
(Collins et al. 2008) have initiated a large-
scale effort to profile the biological activities 
of a large number of chemicals across multiple 
in vitro assays, largely focused on human cel-
lular and molecu  lar targets, and to compile this 
information into predictive models of toxicity. 
Combined approaches using high-throughput 
screening (HTS) and high-content screening 
(HCS) platforms with computational (in silico) 
systems modeling efforts aim to identify sensi-
tive molecular targets of chemicals, the bio-
logical pathways relevant to these targets, and 
their integration into modes of human develop-
mental toxicity. Analysis of the ToxCast data 
set has revealed significant activity across a 
number of biological targets known to partici-
pate in blood vessel formation, maintenance, 
and remodeling. Examining perturbations 
in these crucial processes constitutes a focus 
for predictive modeling and chemical priori-
tization, and this proof-of-concept study on 
a proto  typical toxicity pathway—vascular 
development—demon  strates the opportunity 
to increase mechanistic understanding of pre-
natal health and disease.
The cardio  vascular system is the first organ 
system that develops to a functional state in 
the vertebrate embryo, reflecting the critical 
need for nutrient delivery and waste removal 
(Ferrara 2004). Blood vessel develop  ment 
occurs by two successive processes: vasculo-
genesis, in situ formation of nascent ves-
sels from angio  blasts leading to a primary 
capillary plexus, and expansion of this plexus 
by subsequent pruning and reorganization of 
endothelial cells through angio  genesis (Czirok 
et al. 2008). Disruption of vascular develop-
ment has been directly correlated with pre-
natal loss, mal  formations, maternal placental 
complications, and neuro  developmental 
problems (D’Amato et al. 1994; Ema et al. 
2010; Hanson and Gottesman 2005; Hoyme 
et al. 1990; Klauber et al. 1997; Tideman 
et al. 2007). HTS of a 200-chemical small- 
molecule library in transgenic zebrafish embryos 
has revealed site-specific disruption of vascular 
develop  ment by several mechanistically diverse 
compounds, such as angiotensin-converting 
enzyme inhibitors, micro  tubule inhibitors, and 
estrogenic myco  toxins (Kitambi et al. 2009). 
Thalidomide is perhaps the best-known exam-
ple of a vascular-disruptive develop  mental toxi-
cant. Originally prescribed as an anti  nausea 
agent in the 1960s, the develop  mental toxicity 
of the drug was discovered after thousands of 
tragic cases of skeletal appendicular malforma-
tions, micro  phthalmia, and fetal loss occurred 
in humans (Mellin and Katzenstein 1962). 
It has since been shown to inhibit angio-
genesis (D’Amato et al. 1994) via prevention 
of filopodial extensions from the endothelial 
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Ba c k g r o u n d: Understanding health risks to embryonic development from exposure to environ-
mental chemicals is a significant challenge given the diverse chemical landscape and paucity of 
data for most of these compounds. High-throughput screening (HTS) in the U.S. Environmental 
Protection Agency (EPA) ToxCast™ project provides vast data on an expanding chemical library 
currently consisting of > 1,000 unique compounds across > 500 in vitro assays in phase I (complete) 
and Phase II (under way). This public data set can be used to evaluate concentration-dependent 
effects on many diverse biological targets and build predictive models of prototypical toxicity path-
ways that can aid decision making for assessments of human develop  mental health and disease.
oB j e c t i v e: We mined the ToxCast phase I data set to identify signatures for potential chemical 
disruption of blood vessel formation and remodeling.
Me t h o d s : ToxCast phase I screened 309 chemicals using 467 HTS assays across nine assay tech-
nology platforms. The assays measured direct inter  actions between chemicals and molecular targets 
(receptors, enzymes), as well as downstream effects on reporter gene activity or cellular conse-
quences. We ranked the chemicals according to individual vascular bioactivity score and visualized 
the ranking using ToxPi (Toxicological Priority Index) profiles.
re s u l t s: Targets in inflammatory chemokine signaling, the vascular endothelial growth factor 
pathway, and the plasminogen-activating system were strongly perturbed by some chemicals, and we 
found positive correlations with develop  mental effects from the U.S. EPA ToxRefDB (Toxicological 
Reference Database) in vivo database containing prenatal rat and rabbit guideline studies. We 
observed distinctly different correlative patterns for chemicals with effects in rabbits versus rats, 
despite derivation of in vitro signatures based on human cells and cell-free biochemical targets, imply-
ing conservation but potentially differential contributions of develop  mental pathways among species. 
Follow-up analysis with anti  angiogenic thalidomide analogs and additional in vitro vascular targets 
showed in vitro activity consistent with the most active environmental chemicals tested here. 
co n c l u s i o n s: We predicted that blood vessel development is a target for environmental chemicals 
acting as putative vascular disruptor compounds (pVDCs) and identified potential species differ-
ences in sensitive vascular develop  mental pathways.
key w o r d s : angiogenesis, developmental toxicity, high-throughput screening (HTS), thalidomide, 
vascular development. Environ Health Perspect 119:1596–1603 (2011).  http://dx.doi.org/10.1289/
ehp.1103412 [Online 25 July 2011]Environmental chemicals disrupt angiogenesis pathways
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tip cell in immature embryonic blood vessels 
(Therapontos et al. 2009), leading to secondary 
effects on gene expression, generation of reac-
tive oxygen species, and cell death in neighbor-
ing tissue (Ito et al. 2010; Vargesson 2009).
When analyzing the HTS-HCS data, we 
strive to address several important questions. 
Do environmental chemicals that disrupt blood 
vessel develop  ment also cause develop  mental 
toxicity? For a subset of these chemicals, is the 
disruption of blood vessel develop  ment neces-
sary and sufficient to account for the develop-
mental toxicity? Given the apical, non  specific 
nature of the observed end points in vivo (e.g., 
decreased fetal body weight, delayed skeletal 
ossification), which are typical of regulatory 
guideline develop  mental toxicity studies in 
rats and rabbits, more detailed information is 
required to determine whether vascular disrup-
tion is the true mechanism by which a chemical 
acts. The ToxCast data, covering a wide variety 
of highly specific mechanistic end points, strives 
to meet this need and provide a more in-depth 
description of potential chemical toxicity.
In light of the global importance of 
blood vessel develop  ment in cancer, develop-
mental toxicity, and reproductive effects of 
pharmaceutical compounds, in the present 
study we examined whether putative vascu-
lar disruptor compounds (pVDCs) can be 
used as a class predictor for environmental 
chemicals. Here, we define pVDCs to include 
compounds that may directly perturb pro-
cesses fundamental to vascular develop  ment. 
The mode-of-action processes could include 
vascular patterning–remodeling or utero- 
placental circulation, with specificity that may 
vary depending on mechanisms intrinsic to 
the embryo, placenta, or mother.
Materials and Methods
Source data. Phase I of ToxCast (U.S. EPA 
2010a) employed a chemical library of 309 
unique structures, most of which are registered 
food-use pesticides with extensive animal bio-
assay data available. Chemicals were screened 
using 467 HTS assays across nine assay tech-
nology platforms with active chemicals run in 
concentration-dependent dose–response format 
(Judson et al. 2010). Assays measured direct 
inter  actions between chemi  cals and molecu  lar 
targets (receptors, enzymes), as well as down-
stream effects on reporter gene activity or cellu-
lar consequences. For each assay–chemical   
combination, using automated curve fitting, 
we derived either an AC50 (half-maximal activ-
ity concentration) or LEC (lowest effective 
concentration, statistically significant change 
from controls), where a default value of 1 M 
was assigned for inactive chemicals. Pathway, 
process, and disease-based perturbation scores 
were constructed by mapping assays to genes 
and then to pathways from Gene Ontology 
(GO 2010), Kyoto Encyclopedia of Genes 
and Genomes (KEGG; Kanehisa Laboratories 
2010), Ingenuity Pathways Analysis (IPA; 
Ingenuity Systems Inc., Redwood City, CA), 
Pathway Commons (Memorial Sloan-Kettering 
Cancer Center and the University of Toronto 
2010), and Mouse and Online Mendelian 
Inheritance in Man [OMIM; National Center 
for Biotechnology Information (NCBI) 2010a]
phenotype databases. In brief, a chemical-
pathway perturbation score corresponds to the 
minimum AC50 for that chemical for any assay 
mapping to the pathway, where the chemical 
must show activity (AC50 or LEC) against at 
least five assay targets mapping to genes in the 
pathway. The calculation of these scores has 
been described in detail elsewhere (Judson et al. 
2010). The perturbation scores are a method of 
aggregating assays into groups and providing 
a higher-level view of chemical activity across 
important signaling pathways.
For most of the ToxCast phase I chemi-
cals, in vivo regulatory test guideline data are 
entered into ToxRefDB (Toxicity Reference 
Database; U.S. EPA 2010b). ToxRefDB con-
tains standardized and computable data on 
2-year cancer/chronic studies on rats and mice 
(Martin et al. 2009a), multi  generational repro-
ductive studies on rats (Martin et al. 2009b), 
and pre  natal develop  mental studies on rats and 
rabbits (Knudsen et al. 2009). The database 
includes standardized end points such as fetal 
body weight reduction, pubertal delays, skeletal 
malformations, and tumor formation in adult 
organs. The data are reported as LEL (lowest 
effect level) doses (milli  grams per kilo  gram per 
day) for maternal, develop  mental, or categori-
cal end points. All defect categories (skeletal, 
urogenital, neuro  sensory, etc.) include both 
malformations and variations, which, although 
they may be transitive delays in some cases (e.g., 
dilated renal pelvis), may still represent chemi-
cal effects. In total, there were 76 aggregated 
end points across the ToxRefDB pre  natal stud-
ies. The ToxRefDB annotation system used 
inter  nationally harmonized nomenclature 
(Knudsen et al. 2009; Makris et al. 2009; Wise 
et al. 1997) to create a thesaurus of 988 non-
redundant terms that apply to maternal and 
develop  mental end points (Knudsen et al. 
2009). The complete data set is available for 
download (U.S. EPA 2010b) and is also acces-
sible via a web-searchable format.
Work flow. We probed the ToxCast data 
set for signatures of biological activity that 
could indicate the potential for disrupting 
blood vessel morpho  genesis and remodeling 
(vasculogenesis/angio  genesis). The general 
work flow for identification, prioritization, 
hypothesis generation, and validation of 
pVDCs is shown in Figure 1. To select the 
relevant assays, we used the Virtual Tissues 
Knowledgebase (VT-KB; U.S. EPA 2010c) 
to extract and organize rele  vant facts from the 
scientific literature, using a dictionary of terms 
built with publicly available ontologies of 
genes, pathways, anatomy, clinical outcomes, 
Figure 1. Work flow to identify pVDCs among 309 environmental chemicals. Assays critical to vascular 
development were identified by VT-KB, chemicals were ranked by their VBS against these vascular targets, 
and the ToxPi tool was used to filter/visualize the chemical library. Multivariate algorithms produced pre-
dictive signatures of species-specific vascular disruption, correlated with ToxRefDB in vivo end points in 
prenatal guideline studies. The chemical library was tested against additional reference in vitro assays, and 
reference anti  angiogenic compounds (thalidomide and 5HPP-33) were tested against the pVDC signature.
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and chemicals. We compiled a list of key words 
relevant to embryonic vascular formation 
[see Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1103412)] and cross- 
referenced these with > 300 ToxCast in vitro 
assay targets among 20 million abstracts in 
PubMed (NCBI 2010b). Relevancy of the 
assay targets was determined based on the 
number of cooccurrences with vascular key 
words and biological plausibility. Briefly, the 
vascular key words were first used to extract the 
subset of articles from PubMed that pertain to 
embryonic vascular develop  ment. This database 
of approximately 88,000 articles was named 
VasculoDB. All genes and proteins were then 
ranked by their number of occurrences within 
the abstracts from the VasculoDB and cross- 
referenced with the ToxCast assay targets. Each 
of the highest-ranking assay targets was used 
to perform further key word searches using all 
synonyms of that target [e.g., VEGFR2 (vas-
cular endothelial growth factor receptor 2), 
KDR, VEGFRII, Flk1, etc.] and extract the 
relevant articles for manual full-text evalua-
tion and curation. Biological plausibility was 
determined based on the scientific weight of 
evidence for each target being critical to and 
necessary for embryonic vascular develop  ment.
Chemicals were ranked for vascular- 
disruptive potential by their activity across the 
selected targets. This ranking was referred to 
as a vascular bioactivity score (VBS) and repre-
sented a weighted sum based on the log trans-
form of the AC50/LEC values for the specified 
assay targets [for details, see Supplemental 
Material, pp. 4–5 (http://dx.doi.org/10.1289/
ehp.1103412)]. The 123 chemi  cals that fell 
above the mean score for the entire phase I 
chemical landscape were designated as pVDCs. 
We tested reference thalidomide compounds 
with known anti  angio  genic effects [thalidomide 
and 5-hydroxy-2-(2,6-diisopropylphenyl)-1-
H-isoindole-1,3-dione (5HPP-33); Sigma-
Aldrich Corp., St. Louis, MO] in the identified 
subset of vascular assays (processed under the 
same conditions in rele  vant ToxCast assays) 
and calculated their VBS rankings. We identi-
fied additional assays with biochemical targets 
critical to vascular develop  ment and tested the 
ToxCast chemical library to determine if the 
rank order of activity cor  responded with the 
predicted pVDC potential.
The subset of pVDCs with in vivo develop-
mental toxicity data in ToxRefDB were ana-
lyzed for species-specific trends. We used a 
step  wise linear discriminant analy  sis (LDA) 
with 5-fold cross-validation to identify multi-
variate toxicity signatures based on significant 
associations between groups of pVDCs with 
develop  mental effects specific to rats or rab-
bits and the remainder of the ToxCast in vitro 
assays and pathway perturbation scores. Here 
the independent variables were the in vitro 
assay data, and the dependent variables, or 
predictions, were the groups of pVDCs with 
  species-specific in vivo effects from animal 
testing data in ToxRefDB. The model with 
the best test-set balanced accuracy (BA; aver-
age of sensitivity and specificity) was chosen. 
For algorithm details, example queries, and 
equations, see Supplemental Material, pp. 5–7 
(http://dx.doi.org/10.1289/ehp.1103412). 
Results
Identifying pVDCs. Six assay targets emerged 
as most relevant to embryonic blood vessel 
formation based on biological plausibility 
and prevalence in the VasculoDB literature. 
Figure 2. ToxPi visualization for top 50 pVDCs ranked by VBS across six in vitro targets: CCL2 down-regulation, CXCL10 up-regulation, uPAR up- and down-  regulation, 
PAI-1 up- and down-regulation, VEGFR2 down-regulation, and TIE2 binding. 
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These targets have been previously identified, 
based on murine knock  out models or sig-
nificant associations between biomarker data 
and adverse pregnancy effects, as critical to 
proper embryonic blood vessel formation or 
maternal–fetal placental circulation. In order 
of descending influence (with correspond-
ing references highlighting their importance 
to vascular develop  ment), these were down- 
regulation of the receptor tyrosine kinase 
(RTK) VEGFR2 (Drake et al. 2007); inhi-
bition of the enzymatic activity of TIE2, 
an angio  genic RTK (Patan 1998); down-
regulation of the pro  angio  genic chemokine 
CCL2 (Keeley et al. 2008); perturbation of 
the plasminogen-activating system (PAS) con-
trolling extra  cellular matrix breakdown via 
up- or down-regulation of plasminogen acti-
vator inhibitor type 1 (PAI-1/SERPINE1) 
(Behzadian et al. 2003); up-regulation of the 
pro  inflammatory anti  angio  genic chemokine 
CXCL10 (Romagnani et al. 2001); and pertur-
bation of the PAS via up- or down-  regulation 
of urokinase-type plasminogen activator recep-
tor (uPAR/PLAUR) (D’Alessio and Blasi 
2009). Other ToxCast assay targets broadly 
involved in cell signaling, such as transforming 
growth factor β (TGFβ), had occurrence levels 
comparable to these six features; however, the 
identified features were those deemed to be 
simultaneously highly relevant to embryonic 
vascular develop  ment and specific to those 
cell types that are directly involved in vasculo/
angio  genic processes (endothelial cells, mural 
cells, inflammatory cells). In total, 23 unique 
assays were represented by the six target fea-
tures, including one cell-free biochemical assay 
(Knudsen et al. 2011) and 22 assays com-
bining eight primary human cell types with 
BioMAP (Biologically Multiplexed Activity 
Profiling) protein readouts from complex 
cell-culture mixtures to more closely simulate 
  tissue biology (Houck et al. 2009). 
A VBS was computed as a weighted sum 
of the activity across 23 assays representing 
the six prioritized vascular targets for each 
of 309 unique chemicals in the library. We 
found 123 of 309 chemicals with a VBS above 
the mean score for the entire phase I chemi-
cal landscape and provisionally labeled them 
as pVDCs. The top candidate was pyrida-
ben (VBS = 6.9), and the mean cutoff cor-
responded to cyfluthrin (VBS = 1.48). The 
186 chemicals that did not fall above the mean 
cutoff had a VBS range of 0–1.30. We ranked 
the 309 chemicals according to individual 
VBS and visualized the VBS ranking using 
ToxPi (Toxicological Priority Index) profiles 
(Reif et al. 2010). ToxPi results for the top 
50 pVDCs are shown in Figure 2 [for profiles 
of the entire 309 ToxCast chemical library, see 
Supplemental Material, Figure 2 (http://dx.doi.
org/10.1289/ehp.1103412)]. Each sector is 
normalized to show the relative effect of each 
chemical on each readout, and the overall pro-
files combine the relative weights across VBS 
targets into a single graphic for each pVDC.
Reference thalidomide compounds. 
Statistical models for pVDCs built from 
ToxCast data identified environmental chemi-
cals with no previously known potential to 
disrupt vascular develop  ment. Thalidomide, 
a well-studied develop  mental toxicant, and 
its anti  angio  genic analogue 5HPP-33 are 
known to disrupt blood vessel develop  ment 
(D’Amato et al. 1994; Noguchi et al. 2005; 
Sarkanen et al. 2011). These reference com-
pounds were used to test the pVDC signature 
defined for the ToxCast chemical library. The 
corresponding VBS was derived in the same 
way from s AC50 and s LEC values (Table 1).
As predicted, thalidomide and 5HPP-33 
were active across most of the pVDC signa-
ture assay targets. Both compounds signifi-
cantly down-regulated CCL2 with an LEC 
of 0.625 µM in a coculture of peripheral 
blood mono  nuclear cells and endothelial cells. 
Thalidomide up-regulated PAI-1 in fibro  blasts 
at 40 µM, whereas 5HPP-33 down-regulated 
PAI-1 in both fibroblasts and bronchial epi-
thelial cells (LEC = 20 µM). 5HPP-33 up-
regulated uPAR in bronchial epithelial cells at 
1.25 µM, and thalidomide up-regulated uPAR 
in endothelial cells at 2.5 µM. 5HPP-33 also 
had effects on uPAR in the endothelial cell sys-
tem at 10 µM. Neither compound affected the 
CXCL10 signal assay or produced an AC50 in 
the TIE2 assay. Both compounds, however, fell 
above the mean VBS cutoff and would be clas-
sified as pVDCs based on in vitro activity for 
vascular targets identified by the ToxCast data 
and chemicals. Thalidomide had a lower VBS 
and would be predicted as a moderate vascular 
disruptor, whereas the analog designed spe-
cifically to be anti  angio  genic, 5HPP-33, scored 
the second highest VBS among all 311 com-
pounds tested (ToxPi visualization shown in 
Figure 2). Thus, our findings with reference 
compounds known to be anti  angio  genic sup-
port the contention that VBS is an effective 
metric for vascular disruption.
Reference vascular targets. We expanded 
the initial ToxCast assay portfolio to include 
additional bio  chemical assay targets known 
to be critical in vascular develop  ment: VEGF 
receptors VEGFR1, VEGFR2, and VEGFR3; 
the arterial vessel marker EphB2 (ephrin-B2); 
and PI3Ka (phosphatidyl  inositol 3-kinase) and 
PTEN (phosphatase and tensin homolog), both 
of which have been shown to govern normal 
vascular develop  ment (Chappell et al. 2009; 
Drake et al. 2007; Eichmann et al. 2008; 
Hamada et al. 2005). We hypothesized that 
the ToxCast chemicals predicted to be pVDCs 
would have greater activity on these targets than 
that shown by the remainder of the chemical 
library. The chemical library was run against 
these assays, as was a repeat of the TIE2 assay 
from the original data series (Table 2). Of the 
309 compounds, 14 had one or more AC50 hits 
across these targets. Of these candidates, 11 were 
previously classified as pVDCs based on the 
original portfolio, which involved one biochem-
ical assay (TIE2) and five assays from cell–cell 
signaling platforms. The chemicals in Table 2 
are ranked based on their VBS. The 11 pVDCs 
resulted in 42 AC50 values across these critical 
vascular targets, with an average AC50 of 16 µM, 
Table 1. Reference anti  angiogenic compounds: activity across pVDC signature. 
LEC (µM) TIE2 AC50 
(µM) Chemical VBSa CCL2. CXCL10- uPAR1 PAI‑11 VEGFR2.
5HPP‑33 6.61 0.625 — 1.25 20 20 —
Thalidomide 1.76 0.625 — 2.5 40 — — 
Symbols: ., down-regulation; -, up-regulation; 1, up- and down-regulation; —, no change. 
aSummed activity across 23 assays, corresponding to the 6 assay targets shown here. 
Table 2. Chemical activities (AC50) across biochemical targets critical to vascular development. 
AC50 (µM)
ToxCast chemical name VBS VEGFR1 VEGFR2 VEGFR3 TIE2 EphB2 PI3Ka PTEN
Predicted pVDCs from ToxCast data
Abamectin 5.19 38.8 17 6.4
Maneb 4.69 4.1 31 12 8.08 23 0.9
Metiram‑zinc 4.35 6.6 41 22 15 29 12
Oxytetracycline dihydrate 3.85 19 6.5 15 6.2 1.6
Perfluorooctanesulfonic acid 3.48 8.2 50 8 4.43 6.5 17
Perfluorooctanoic acid 3.04 31.9
Mancozeb 3.00 19 5.9 1.3 10.4 21 20 0.23
Emamectin benzoate 2.91 21 7.9 2.1
2,2‑bis‑(p‑Hydroxyphenyl)‑1,1,1‑trichloroethane 2.28 28
Diclosulam 2.09 50
Milbemectin 1.49 20 11 12
Predicted non‑pVDCs from ToxCast data 
Captan 1.14             35
Cyclanilide 0.21 50 3.9
Sethoxydim 0.00 22Kleinstreuer et al.
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whereas the three non-pVDCs resulted in four 
AC50 values, with an average value of 28 µM. 
The results from these assays revealed a trend 
whereby pVDCs with a higher VBS had lower 
AC50 values (30 values ≤ 20 µM) across a wider 
variety of vascular targets, whereas compounds 
that did not make the pVDC cutoff had higher 
AC50 values (one value ≤ 20 µM) for a more 
limited number of targets. These additional data 
for more targets in vascular pathways further 
demonstrated that VBS is an effective tool iden-
tifying vascular disruptors.
Correlations with in vivo animal data. 
Most ToxCast chemicals have corresponding 
in vivo bioassay data in ToxRefDB (Knudsen 
et al. 2009; Martin et al. 2009a, 2009b), a 
standardized and computable database that 
includes 76 aggregated end points across rat 
and rabbit pre  natal develop  mental toxic-
ity studies (U.S. EPA 2010b). The candidate 
pVDCs were cross-referenced to ToxRefDB 
develop  mental effects [for a list of pVDCs 
(n = 17) without pre  natal guideline study 
data in either species, see Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1103412)]. Many of those chemicals, such 
as imazalil and perfluoro  octanoic acid, are 
known from the literature to have mammalian 
develop  mental toxicity (Lau et al. 2004; Zega 
et al. 2009), and these data were captured by 
the VT-KB and reported, where applicable [for 
a list of pVDCs that did not have a recorded 
develop  mental effect or result in pregnancy-
related fetal loss in rat or rabbit (n = 7), see 
Supplemental Material, Table 2]. In addition 
to the correlations with end points from the 
pre  natal literature, toxicity was exhibited across 
a wide range of biological systems in chronic 
and multi  generational guideline studies; the 
most common end points recorded were liver 
and kidney effects.
For pVDCs with data in both rat and 
rabbit (n = 84), adverse effects directly on 
the embryo were seen with 68% of chemi-
cals. In rabbits, the most numerous end points 
(k) were embryonic fetal loss (k = 23), skele-
tal axial defects (k = 17), and fetal weight 
reduction (k = 15). In rats, the most preva  lent 
end points were skeletal axial defects (k = 40), 
fetal weight reduction (k = 30), embryonic fetal 
loss (k = 21), and skeletal appendicular defects 
(k = 16). The category of skeletal defects poten-
tially shows high representation because bone 
elements, such as vertebrae, femur, and ribs, are 
entered into the database as individual targets 
and further annotated by descriptions such as 
absent, incomplete ossification, or misshapen. 
In the ToxRefDB ontology, maternal effects 
are recorded separately. In cases of increased 
resorptions and fetal losses, it is not possible 
to know whether these effects were maternal 
or embryo mediated. Pregnancy-related fetal 
loss (all expressions of fetal wastage, includ-
ing pre  implantation loss, implantation failure, 
resorptions, and fetal death) was a distinct cat-
egory entered into ToxRefDB that may also be 
indicative of embryo  toxicity, and if this addi-
tional end point is included, the number of 
potentially develop  mentally toxic pVDCs with 
pre  natal data in both rats and rabbits increased 
from 68% to 92%. This was the most preva-
lent end point in the rabbit (k = 32) and also 
occurred in the rat (k = 20).
Species-specific signatures. We observed 
a striking difference between the subsets of 
pVDCs active in pregnant rats versus rabbits, 
which raised two important questions about 
predictive modeling useful for informing 
human health risk assessments. First, can the 
same suite of in vitro assays based primarily 
on human cells and biochemical targets pro-
vide a signature that distinguishes chemicals 
develop  mentally toxic in rabbits from those 
develop  mentally toxic in rats? Second, what 
distinguishes pathway-level perturbations by 
chemicals that affect one species differently 
from the other?
Among pVDCs tested in both species 
and entered into ToxRefDB, 22 candidates 
exhibited develop  mental toxicity in the rab-
bit only (Table 3), and 21 chemicals resulted 
in develop  mental phenotypes in the rat only 
(Table 4). Each subset of species-specific 
pVDCs was run through a step  wise LDA to 
determine commonalities among their bio-
activity profiles and to identify susceptible 
Table 4. pVDCs with rat-specific effects in ToxRefDB prenatal studies.
Chemical VBS Developmental phenotype
Diniconazole 4.57 General fetal pathology; embryo fetal loss; maternal pregnancy loss; skeletal: 
appendicular, axial; urogenital: renal
Naled 4.22 Embryo fetal loss; trunk: body wall
(Z,E)‑Fenpyroximate 3.88 Skeletal: axial
Cyazofamid 3.34 Skeletal: axial
Chlorothalonil 3.28 Embryo fetal loss; maternal pregnancy loss
Lactofen 3.18 Fetal weight reduction; maternal pregnancy loss; skeletal: appendicular; skeletal: axial
Spirodiclofen 3.15 Urogenital: renal
Thiodicarb 2.97 Fetal weight reduction, general fetal pathology; embryo fetal loss; maternal 
pregnancy loss; skeletal: axial
Alachlor 2.97 Fetal weight reduction; embryo fetal loss
Emamectin benzoate 2.91 Fetal weight reduction; skeletal: appendicular, axial, cranial
Fluoxastrobin 2.79 Skeletal: appendicular
Hexythiazox 2.78 Skeletal: appendicular
Tetraconazole 2.23 General fetal pathology; skeletal: axial; urogenital: renal, ureteric
Prodiamine 2.19 Neurosensory: eye
Fenpropathrin 2.18 Maternal pregnancy loss
Acetochlor 2.16 Fetal weight reduction; general fetal pathology; embryo fetal loss; maternal 
pregnancy loss; skeletal: axial
Prallethrin 2.11 Maternal pregnancy loss
Thiazopyr 2.00 Skeletal: axial
Fludioxonil 1.82 Urogenital: renal, ureteric
Profenofos 1.71 Maternal pregnancy loss
Metolachlor 1.57 Fetal weight reduction; embryo fetal loss; maternal pregnancy loss
Table 3. pVDCs with rabbit-specific effects in ToxRefDB prenatal studies.
Chemical VBS Developmental phenotype
Methylene bis(thiocyanate) 6.55 Maternal pregnancy loss
Trifloxystrobin 4.26 Skeletal: axial
Propargite 3.79 Skeletal: axial
Etoxazole 3.66 Skeletal: axial
Fenoxycarb 3.60 Skeletal: axial
Azamethiphos 3.10 Maternal pregnancy loss
Quinoxyfen 3.02 Maternal pregnancy loss
Butafenacil 2.94 Embryo fetal loss
Dazomet 2.61 General fetal pathology; embryo fetal loss; skeletal: axial
Rimsulfuron 2.52 Embryo fetal loss; maternal pregnancy loss
Dichlorvos 2.34 Maternal pregnancy loss
Bensulide 2.17 Maternal pregnancy loss
Flumiclorac‑pentyl 2.11 Maternal pregnancy loss
Diclosulam 2.09 Maternal pregnancy loss
Propetamphos 2.08 Embryo fetal loss
Butachlor 1.99 Fetal weight reduction; embryo fetal loss; maternal pregnancy loss
Dicofol 1.92 Maternal pregnancy loss
Oxyfluorfen 1.82 Embryo fetal loss; maternal pregnancy loss
Famoxadone 1.82 Embryo fetal loss; maternal pregnancy loss
Flufenpyr‑ethyl 1.73 Maternal pregnancy loss
Dicrotophos 1.59 Fetal weight reduction; maternal pregnancy loss
Carboxin 1.56 Maternal pregnancy lossEnvironmental chemicals disrupt angiogenesis pathways
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systems that can account for the cross-species 
differences. In each case we considered the 
set of pVDCs that were tested in both spe-
cies, where the model positives were those that 
showed effects specific to one species and the 
negatives were the remainder of the set. The 
algorithm was run several times with varying 
feature sets allowing for linear combinations 
of in vitro assays, in vivo data, and pathway 
perturbation scores, and we chose the model 
with best cross-validation test BA. Running 
the algorithm with the same feature set several 
times did not produce different BAs, so the 
model was assumed to be stable.
Remarkably, the statistical model pre-
dicted that the PAS was a significant target for 
pVDCs active in the rabbit but not rat studies. 
The best predictive signature was capable of 
identifying with 80% accuracy rabbit-specific 
develop  mental toxi  cants that may be work-
ing via a vascular-disruptive mechanism (test 
BA = 0.8 over 20 itera  tions). Table 5 shows 
the model features, which include down- 
regulation of PAI-1 in a complex culture assay 
of bronchial epithelial cells and a group of 
pathways from databases such as GO, IPA, 
and KEGG. Many of the pathways being tar-
geted by these compounds are related to inter-
actions with the extracellular matrix and the 
PAS and include processes such as regulation 
of angio  genesis, fibrinolysis, collagen binding, 
blood coagulation, and trans  membrane recep-
tor activity. Other perturbed pathways, such 
as regulation of apoptosis and p53 signaling, 
pertain to cellular survival and programmed 
cell death critical to proper embryonic 
develop  ment. When run against a feature set 
consisting of only the ToxCast assays, the sig-
nature had lower predictivity (test BA = 0.6) 
but was still focused on elements of the PAS, 
with down-regulation and up-regulation of 
PAI-1 emerging as the two strongest com-
ponents. This signature is represented by 
the rabbit ToxPi in Figure 1. The pattern of 
in vivo end points caused by the rabbit-specific 
pVDCs (Table 3) was nearly uniform, with 
18 of 22 (82%) resulting in either embryonic 
loss or maternal pregnancy loss and 5 of 22 
resulting in skeletal axial defects (dazomet 
affected both end points and caused general 
fetal pathology). Fetal weight reduction was 
also due to butachlor and dicroto  phos in 
ToxRefDB (U.S. EPA 2010b). 
In contrast, pVDCs that were active in the 
rat but not in rabbit prenatal studies (Table 4) 
were significantly associated with inflamma-
tory response targets. The signature was able to 
identify with 90% accuracy rat-specific develop-
mental toxicants that may be acting via a   
vascular-disruptive mechanism (cross-  validation 
BA = 0.9). The model features (Table 6) con-
sisted of three assays: CCL2 down-regulation 
in a complex coculture of peripheral blood 
mononuclear cells and endothelial cells, CD40 
down-regulation in the same system, and a cell 
viability assay in the HepG2 human hepato-
cellular carcinoma cell line. This model was 
produced by a feature set containing only the 
ToxCast assays. When run against a feature 
set including pathway perturbation scores, the 
same signature is produced with one additional 
feature, the GO pathway “Component: integral 
to membrane,” and a slightly lower BA = 0.84 
(data not shown). These compounds appear to 
be preferentially targeting inflammatory sig-
naling, specifically via the angio  genic chemo-
kine CCL2 and CD40, a tumor necrosis factor 
receptor family protein that controls a variety 
of immune-related processes and is expressed 
by vascular endothelial cells and macrophages, 
among others. The downstream effects of per-
turbing CD40/chemokine signaling involve 
interruption of cell–cell adhesion and prolifera-
tion, which could correlate with the cell loss 
observed in HepG2 cells at the 72-hr time 
point. In vivo end points caused by the rat-
specific pVDCs were more diverse, with fetal 
loss being less common (10 of 21) than in the 
rabbit and a wider variety of phenotypes, with 
the most common being axial and appendicular 
skele  tal defects. We also observed urogenital 
end points (due to diniconazole, spirodiclofen, 
tetraconazole, and fludioxonil) and fetal weight 
reduction in ToxRefDB (U.S. EPA 2010b).
Discussion
These results provide a novel ranking of 
environ  mental chemicals based on potential 
to disrupt critical targets in vascular develop-
ment and suggest a strong association with the 
potential for adverse develop  mental effects in 
pregnant rats or rabbits. This finding frames the 
hypothesis that vascularization of the embryo–
placenta is a common biological target for the 
develop  mental toxicity of some environmental 
chemicals that act as pVDCs. The two most 
prevalent effects in the animal prenatal testing, 
skeletal malformation and fetal loss, further 
suggest that pVDCs act on different aspects 
of vascular signaling, including the VEGF 
pathway, the PAS, and the chemo  kine signal-
ing network. Deeper examination of ToxCast 
chemicals also revealed a species-specific in vivo 
response in the inflammatory signaling net-
work (rats) and the PAS (rabbits). It is note-
worthy that the reference compounds tested 
here (thalidomide, 5HPP-33) produced results 
consistent with the observed vascular disrup-
tion signature. This study demon  strates the use 
of rapid in vitro testing to rank and prioritize 
Table 5. Multivariate toxicity signature: pVDCs with rabbit-specific effects in ToxRefDB prenatal studies.
Descriptor Result
Model statistics
Learner LDA
CV 5‑fold
BA train 0.86
BA test 0.8
Best sensitivity 0.84
Best specificity 0.84
Best AUC 0.86
Model features
Pathways
Gene SERPINE1 (PAI‑1); MMP9
GO: Process Regulation of angiogenesis; fibrinolysis; blood coagulation; positive regulation of apoptosis
KEGG p53 signaling pathway; complement coagulation cascades
IPA  Coagulation system; acute phase response signaling
GO: Function Serine type endopeptidase activity; transmembrane receptor activity; collagen binding
GO: Component Extracellular region; integral to membrane
ToxCast assays BSK:BE3C (bronchial epithelial cells): PAI‑1 down
Abbreviations: AUC, area under receiver operating characteristic curve; BA, balanced accuracy; CV, cross valida-
tion; MMP9, matrix metalloproteinase 9. Pathways were output from different annotations, including GO (2010), KEGG 
(Kanehisa Laboratories 2010), and PathwayCommons (Memorial Sloan-Kettering Cancer Center and the University of 
Toronto 2010). 
Table 6. Multivariate toxicity signature: pVDCs with rat-specific effects in ToxRefDB prenatal studies.
Descriptor Result
Model statistics
Learner LDA
CV 5‑fold
BA train 0.9
BA test 0.9
Best sensitivity 0.9
Best specificity 0.9
Best AUC 0.9
Model features
ToxCast assays BSK:SAg (peripheral blood mononuclear cells + endothelial cells): CCL2 down, CD40 down
CLM (HepG2 human hepatocellular carcinoma cell line): cell loss 72‑hr time point
Abbreviations: AUC, area under receiver operating characteristic curve; BA, balanced accuracy; CV, cross-validation. Kleinstreuer et al.
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environ  mental chemi  cal libraries to identify 
compounds with the potential for vascular dis-
ruption. We developed a phenomenological 
vascular-disruptive toxicity signature based on 
short-term assay information and showed that 
the most compounds identified by this signa-
ture also caused in vivo develop  mental toxicity.
Prenatal guideline studies in vivo record 
predominantly apical end points with insuffi-
cient detail to determine whether the observed 
develop  mental toxicity is via vascular disrup-
tion or some other mechanism. One would 
expect that most pVDCs would be potential 
develop  mental toxicants, as is the case here 
(92%), but not that all develop  mental toxi-
cants would be pVDCs. Of the remaining 
ToxCast phase I compounds (non-pVDCs) 
with prenatal guideline studies in both species 
(n = 130), 75% have direct embryonic effects 
or pregnancy-related fetal loss recorded in 
ToxRefDB, and we would predict that those 
effects are via a mechanism other than vascu-
lar disruption. We were unable to find any 
statistically significant concordance between 
the potency of the AC50 values in vitro and the 
incidence or pattern of develop  mental effects 
due to the ToxCast compounds, pVDC or 
otherwise (Sipes et al. 2011).
Many vascular-active develop  mental toxi-
cants from the literature show concordance with 
the signaling pathways and specific targets iden-
tified in this analysis. The first anti  angio  genic 
compound to be assessed in clinical trials, TNP-
470 (O-[chloroacetyl-carbamoyl]fumagillol), 
resulted in spontaneous resorption and intra-
uterine growth restriction when administered 
early or late in murine pregnancy, respectively 
(Rutland et al. 2005). Targeted examination 
of TNP-470’s effect on the ocular vasculature 
revealed a significant decrease in VEGF expres-
sion and VEGFR2 phosphorylation (Joussen 
et al. 2001; Satchi-Fainaro et al. 2005). Placental 
vascular remodeling was suppressed in rats after 
exposure to the develop  mental toxi  cant 2,3,7,8-
tetrachloro  dibenzo-p-dioxin (TCDD) and was 
significantly correlated with decreased expres-
sion of TIE2 mRNA (Ishimura et al. 2009). 
Angiostatin is a naturally occurring product of 
the PAS from the cleavage of plasminogen with 
strong inhibitory effects on blood vessel forma-
tion in vivo (Jing et al. 2004). Thalidomide is an 
anti  angio  genic compound that has been studied 
for > 40 years and was shown here to target 
inflammatory signaling and extra  cellular matrix 
breakdown via the PAS. This corresponds to 
the pattern of genetic perturbations of vascular 
signaling found in a recent study in pregnant 
monkeys (Ema et al. 2010). The thalidomide 
analog 5HPP-33 was shown to have potent 
anti  angio  genic activity in a human umbilical 
vein endothelial cell assay (~ 60% inhibition of 
tube formation), whereas the parent compound 
had moderate activity (~ 30% inhibition of tube 
formation) (Noguchi et al. 2005). When tested 
against our signature, both compounds were 
classified as pVDCs; however, 5HPP-33 was 
predicted to be more strongly anti  angio  genic 
than the parent compound, as expected.
An intriguing result of this analysis is the 
emergence of a possible species-specific signa-
ture that may shed light on the mecha  nisms 
under  lying differential effects in animal studies. 
A subset of chemicals with rat-specific develop-
mental toxicity correlated with down-regulation 
of pro  inflammatory chemokine assays, whereas 
the subset of chemi  cals with rabbit-specific 
activity resulted in up-regulation of these   
signals. We observed a bias toward targets in 
the PAS and extra  cellular regions by rabbit- 
specific chemicals, with greater bio  activity across 
assay end points such as PAI-1. The observed 
develop  mental toxicity also showed a differen-
tial response across species, with higher inci-
dences of skeletal deformation in rat studies and 
of prenatal death in rabbit studies. Recent work 
has shown that a functional overlap of plasmi-
nogen and matrix metalloproteinases (MMPs) 
regulates placental vascularization (Solberg et al. 
2003). Additionally, the hemostatic challenge 
of placentation requires a shift from an anti- to 
a pro  coagulant state (Li and Huang 2009), and 
the rabbit-specific pVDCs were correlated with 
several blood coagulation pathways. We specu-
late that pVDCs have a strong effect on placen-
tation in the rabbit, leading to prenatal death, 
whereas the vascular-disruptive mechanism in 
the rat may be acting farther downstream via 
the inflammatory system and targeting vessel 
remodeling of the forming skele  tal system. The 
signature derived here would have predicted 
that thalidomide, because of its impact on 
the PAS, would affect the developing rabbit. 
Figure 3. Vascular developmental signaling pathways identified by pVDC signature and hypothesized 
species-specific target sites. Rabbit-specific developmental toxicants potentially target the PAS (e.g., PAI-1, 
uPAR), and rat-specific developmental toxicants potentially target inflammatory chemokine signaling (e.g., 
CXCL10, CCL2). The VEGF and ANG/TIE2 pathways are critical pathways associated with developmental 
toxicity across species. Abbreviations: ANG, angiopoietin; Elk-1, ETS-like transcription factor 1; GPI, glycosyl-
phosphatidylinositol; JAK/STAT, Janus kinase/signal transducer and activator of transcription; MMP, matrix 
metalloproteinase; NFKB, nuclear factor kappa B; PLC/IP3, phospholipase C/inositol triphosphate; P13K/
AKT, phosphatidylinositol 3-kinase/protein kinase B; SHC/RAS/MAPK/ERK 1&2, Src homology 2 domain 
containing proteins/RAt sarcoma family/mitogen-activated protein kinases/extracellular-signal-regulated 
kinases 1 and 2; SRC/FAK, sarcoma tyrosine kinase/focal adhesion kinase.
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Such has been confirmed many times in vivo, 
although the mechanism was attributed to 
redox imbalance rather than anti  angio  genesis 
(Hansen et al. 2001). To our knowledge, 
5HPP-33 has not been tested in pregnant rats 
or rabbits, but the VEGFR2 signature effect 
would lead us to predict that it would interrupt 
vascular develop  ment across species. Figure 3 
depicts an overview of vascular develop  mental 
signaling involved in the pVDC signature and 
the proposed species-specific target pathways, 
where chemicals preferentially affecting the rab-
bit may be acting on the PAS and those prefer-
entially affecting the rat may be more strongly 
perturbing inflammatory signaling.
Although there is no doubt that conserva-
tion of vascular develop  mental pathways across 
species exists, the relative importance of these 
pathways may differ in each species. Similarly, 
the consequences of disrupting these pathways 
may be species specific. Species-specific differ-
ences in pharmaco    kinetics could contribute 
to variations in develop  mental effects due to 
chemical insult, as well as affecting in vitro to 
in vivo predictions. Because of inter  correlation 
among assays and pathways, there is a poten-
tial for over  fitting of the models. Continued 
investigation is required to increase our under-
standing of this potential connection between 
develop  mental toxicity and vascular disruption 
and further delineate which elements of these 
signatures are most useful in predicting and 
modeling potential effects in humans.
The pVDC toxicity signature represents 
an important tool in evaluating the vascular-
disruptive potential of environmental chemi-
cals. Although ToxCast HTS data and other 
information may not yet be sufficient to pre-
dict develop  mental toxicity in animals and 
humans, it is providing unique and valuable 
mechanistic information on proto  typical tox-
icity pathways such as vascular disruption that 
could assist in chemical prioritization and fur-
ther targeted testing.
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